Skip to main content

Table 3 Baseline demographics and clinical findings -for initial CTD-ILD vs non-CTD-ILD diagnoses in serology screened patients

From: Utility of autoimmune serology testing in the assessment of uncharacterized interstitial lung disease: a large retrospective cohort review

 

Diagnosed CTD-ILD (N = 42)

Non-CTD-ILD (N = 563)

P-value

Age (mean ± SD)

61.0 ± 11.0

67.0 ± 11.5

0.001

Sex

 Male, N(%)

23 (54.8)

337 (59.9)

0.760

 Female, N(%)

19 (45.2)

226 (40.1)

 

Smoking

 Nonsmoker, N(%)

21 (50)

219 (38.9)

0.002

 Ex-smoker, N(%)

19 (45.2)

334 (59.3)

 Active smoker, N(%)

2 (4.8)

10 (1.8)

ROS positive, N(%)

39 (92.9)

89 (15.8)

<0.001

Positive serology

41(97.6)

172 (30.6)

<0.001

TLC% (mean ± SD)

71.5 ± 17.1

72.7 ± 16.7

0.471

FVC%(mean ± SD)

67.5 ± 16.3

69.0 ± 19.0

0.278

DLCO% (mean ± SD)

49.0 ± 17.8

51.8 ± 16.1

0.315

Frequency of selected positive serology tests, N(%)

   

ANA

29 (69)

82 (14.6)

<0.001

RF

13 (31)

38 (6.7)

<0.001

SS-A/SS-B

16 (38.1)

22 (3.9)

<0.001

Anti CCP

7 (16.7)

10 (1.8)

<0.001

Scl-70

6 (14.3)

4 (0.71)

<0.001

Anti Jo

3 (7.1)

1 (0.17)

<0.001

RNP

3 (7.1)

21 (3.7)

0.274

Positive clinical signs or symptoms, N (%)

   

Raynaud’s phenomenon

16 (38)

15 (2.6)

<0.0001

Sicca symptoms

7 (16.6)

24 (4.2)

0.0004

Arthralgias/synovitis

19 (45)

44 (7.8)

<0.0001

Rash/photosensitivity

4 (9.5)

19 (3.4)

0.04

Myalgia/weakness

7 (16.6)

14 (2.5)

<0.0001

Mechanic hands

2 (4.8)

1 (0.1)

<0.0001

Gottron papules

1 (2.3)

0 (0)

0.0002

Dysphagia

5 (11.9)

7 (1.2)

<0.0001

Fatigue/malaise/fever

4 (9.5)

8 (1.4)

0.0003

  1. Abbreviations: ANA antinuclear antibody, CCP Cyclic citrullinated peptide antibody, CTD connective tissue diseases, DLCO% percent diffusing capacity for carbon monoxide, FVC% percent forced vital capacity, RF Rheumatoid factor, ROS review of systems, Scl 70 scleroderma topoisomerase 70 antibody, SD standard deviation, SS-A anti-Sjögren’s syndrome A antibody, SS-B anti-Sjögren’s syndrome B antibody, TLC% percent total lung capacity, RNP ribonucleotide protein antibody